Tag Archives: psp

The Influence of PSP on the Behavior and Growth of the Fetus in Rats.

Zheng-de Zhang1, Zhen-bin Qian2, Lan-feng Zhou2 and Bin Xu1 1 Shanghai Institute of Materia Medica, Academia Sinica 2 Department of Toxicology, Shanghai Institute of Labour Health and Occupational Diseases


PSP is a new immunomodulating agent prepared and developed by Professor Qing-yao Yang. In the present work its influence on the behavior and growth of fetus in 1st and 2nd generation of rats was investigated.

For behavior study the squirrel wheel test, rotating cylinder test and passive avoidance test were performed, PSP was administered orally at 60, 600 and 6000mg/kg. The results showed that no marked difference in the change of behavior was found between the control and treatment groups. The brain weights of two-generation rats had no marked change either.

For teratogeny test 110 rats were involved PSP was administered orally at 60, 600 and 6000mg/kg in different groups for 10 days. The conditions of the maternal body, embryonic survival and the function and growth of the fetuses were examined. After statistical tests no marked difference was observed in the control and treatment groups.

The data observed showed that PSP has no noticeable toxicity on fetus growth and on the behavioral performance of 1st and 2nd generation rats

(Click Here for Detail)

Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice.

Wu D, Han SN, Bronson RT, Smith DE, Meydani SN.

Nutritional Immunology Laboratory, Jean Mayer U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA.


Decline in immune response is a well-documented age-associated biological change. Protein-bound polysaccharides (PSP) are biological response modifiers and have been shown to have immunoenhancing and antitumor effects. This study was conducted to examine the effect of dietary supplementation with PSP-containing extract derived from mycelia of Coriolus versicolor on in vitro and in vivo indices of immune function of young and old mice. Young (5 mo) and old (23 mo) C57BL/6NIA mice were fed purified diets containing 0, 0.1, 0.5 or 1.0% PSP for 1 mo at which time indices of immune function were measured. PSP supplementation had no significant effect on mitogenic response to concanavalin A (Con A), phytohemagglutinin (PHA) or lipopolysaccharide (LPS), or on production of interleukin (IL)-1, IL-2, IL- 4 and prostaglandin E2 (PGE2). Of the in vivo indices of immune function tested, old mice fed 1.0% PSP had significantly higher delayed-type hypersensitivity (DTH) response than those fed 0% PSP. No significant effect of PSP was observed on the DTH response of young mice. The antibody response to sheep red blood cells was not significantly influenced by PSP in young or old mice. These results suggest that PSP-containing extract from mycelia of Coriolus versicolor might have a modest immunoenhancing effect in aged mice, but not in young mice.

PMID: 9446842 [PubMed – indexed for MEDLINE]Free Article


Modulation of antipyrine clearance by polysaccharide peptide (PSP) isolated from Coriolus versicolor in the rat.

Chan SL, Yeung JH.

Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China.


Polysaccharide peptide (PSP), isolated from Coriolus versicolor COV-1, has been previously shown to have immuno-stimulatory, anti-tumour and analgesic effects in animal models. When used as an adjunct in cancer chemotherapy in clinical trials carried out in China, PSP improved the quality of life in the patients by improving appetite and alleviating symptoms associated with cancer chemotherapy. In this study, the effects of non-toxic doses of PSP on phase I metabolism was investigated in the rat, using the conventional probe antipyrine. Acute PSP (3-5 micromol/kg, i.p.) treatment did not produce significant changes in antipyrine clearance. Sub-chronic treatment with PSP (1-3 micromol/kg/day, i.p., 3 days) decreased the antipyrine clearance (30-35%), with an increase in the plasma half-life (T1/2) by 55% and an increase in the area under concentration-time curve (AUC) by 61%. Total hepatic cytochrome P450 (P450) was dose-dependently decreased (32-54%) after sub-chronic, but not the acute treatment of PSP. Given that PSP can affect phase I metabolism and hepatic cytochrome P450 content, the concomitant use of PSP with other therapeutic agents that undergo phase I metabolism should be carefully monitored.

PMID: 16698162 [PubMed – indexed for MEDLINE]